In addition, human epidermal growth factor receptor 2 (HER2), a tyrosine kinase receptor of the EGFR family, is overexpressed in 30% of patients with breast cancer, and resistance can develop following long-term use of inhibitors targeting this receptor34. This evidence concerns the gene ERBB2 and breast carcinoma.